These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 23575412)

  • 1. Histology and smoking status predict survival of patients with advanced non-small-cell lung cancer. Results of West Japan Oncology Group (WJOG) Study 3906L.
    Kogure Y; Ando M; Saka H; Chiba Y; Yamamoto N; Asami K; Hirashima T; Seto T; Nagase S; Otsuka K; Yanagihara K; Takeda K; Okamoto I; Aoki T; Takayama K; Yamasaki M; Kudoh S; Katakami N; Miyazaki M; Nakagawa K
    J Thorac Oncol; 2013 Jun; 8(6):753-8. PubMed ID: 23575412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized phase 2 study of paclitaxel and carboplatin with or without conatumumab for first-line treatment of advanced non-small-cell lung cancer.
    Paz-Ares L; Bálint B; de Boer RH; van Meerbeeck JP; Wierzbicki R; De Souza P; Galimi F; Haddad V; Sabin T; Hei YJ; Pan Y; Cottrell S; Hsu CP; RamLau R
    J Thorac Oncol; 2013 Mar; 8(3):329-37. PubMed ID: 23370314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC.
    Kawaguchi T; Takada M; Kubo A; Matsumura A; Fukai S; Tamura A; Saito R; Maruyama Y; Kawahara M; Ignatius Ou SH
    J Thorac Oncol; 2010 May; 5(5):620-30. PubMed ID: 20354456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neoadjuvant chemotherapy with docetaxel-cisplatin in patients with stage III N2 non-small-cell lung cancer.
    Liao WY; Chen JH; Wu M; Shih JY; Chen KY; Ho CC; Yang JC; Yu CJ
    Clin Lung Cancer; 2013 Jul; 14(4):418-24. PubMed ID: 23291258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 2 study of frontline bortezomib in patients with advanced non-small cell lung cancer.
    Besse B; Planchard D; Veillard AS; Taillade L; Khayat D; Ducourtieux M; Pignon JP; Lumbroso J; Lafontaine C; Mathiot C; Soria JC
    Lung Cancer; 2012 Apr; 76(1):78-83. PubMed ID: 22186627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors.
    Chen KY; Chen JH; Shih JY; Yang CH; Yu CJ; Yang PC
    J Thorac Oncol; 2010 Jan; 5(1):82-9. PubMed ID: 19884854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serpin b3 is associated with poor survival after chemotherapy and is a potential novel predictive biomarker in advanced non-small-cell lung cancer.
    Urquhart G; Kerr KM; Nicolson M; Loo PS; Sharma R; Shrimali R; Petty RD
    J Thorac Oncol; 2013 Dec; 8(12):1502-9. PubMed ID: 24389432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lung cancer in women, a different disease: survival differences by sex in Turkey.
    Ulas A; Tokluoglu S; Kos M; Silay K; Akinci S; Oksuzoglu B; Alkis N
    Asian Pac J Cancer Prev; 2015; 16(2):815-22. PubMed ID: 25684531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First-line gefitinib treatment for patients with advanced non-small cell lung cancer with poor performance status.
    Lee YJ; Kim HT; Han JY; Yun T; Lee GK; Kim HY; Sung JH; Lee JS
    J Thorac Oncol; 2010 Mar; 5(3):361-8. PubMed ID: 20107420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement in population-based survival of stage IV NSCLC due to increased use of chemotherapy.
    Aarts MJ; van den Borne BE; Biesma B; Kloover JS; Aerts JG; Lemmens VE
    Int J Cancer; 2015 Mar; 136(5):E387-95. PubMed ID: 25219898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic value of ratio-based lymph node staging in resected non-small-cell lung cancer.
    Qiu C; Dong W; Su B; Liu Q; Du J
    J Thorac Oncol; 2013 Apr; 8(4):429-35. PubMed ID: 23486264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study).
    Van Meerbeeck J; Galdermans D; Bustin F; De Vos L; Lechat I; Abraham I
    Eur J Cancer Care (Engl); 2014 May; 23(3):370-9. PubMed ID: 24152297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
    Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Zhao YD; Liepa AM; Peterson P; Tonato M
    J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized phase II study of cetuximab and bevacizumab in combination with two regimens of paclitaxel and carboplatin in chemonaive patients with stage IIIB/IV non-small-cell lung cancer.
    Bonomi PD; Mace J; Mandanas RA; Min M; Olsen M; Youssoufian H; Katz TL; Sheth G; Lee HJ
    J Thorac Oncol; 2013 Mar; 8(3):338-45. PubMed ID: 23370316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of number of resected and involved lymph nodes at complete resection on survival in non-small cell lung cancer.
    Saji H; Tsuboi M; Yoshida K; Kato Y; Nomura M; Matsubayashi J; Nagao T; Kakihana M; Usuda J; Kajiwara N; Ohira T; Ikeda N
    J Thorac Oncol; 2011 Nov; 6(11):1865-71. PubMed ID: 21964529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated expression of BIRC6 protein in non-small-cell lung cancers is associated with cancer recurrence and chemoresistance.
    Dong X; Lin D; Low C; Vucic EA; English JC; Yee J; Murray N; Lam WL; Ling V; Lam S; Gout PW; Wang Y
    J Thorac Oncol; 2013 Feb; 8(2):161-70. PubMed ID: 23287853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcome of treated advanced non-small cell lung cancer with and without central airway obstruction.
    Chhajed PN; Baty F; Pless M; Somandin S; Tamm M; Brutsche MH
    Chest; 2006 Dec; 130(6):1803-7. PubMed ID: 17167000
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospective analysis of third-line chemotherapy in advanced non-small cell lung cancer.
    Tatli AM; Arslan D; Uysal M; Goksu SS; Gunduz SG; Coskun HS; Ozdogan M; Savas B; Bozcuk HS
    J Cancer Res Ther; 2015; 11(4):805-9. PubMed ID: 26881522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retrospective analysis of third-line and fourth-line chemotherapy for advanced non-small-cell lung cancer.
    Asahina H; Sekine I; Horinouchi H; Nokihara H; Yamamoto N; Kubota K; Tamura T
    Clin Lung Cancer; 2012 Jan; 13(1):39-43. PubMed ID: 21890422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized phase 3 trial comparing pemetrexed/carboplatin and docetaxel/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer.
    Rodrigues-Pereira J; Kim JH; Magallanes M; Lee DH; Wang J; Ganju V; Martínez-Barrera L; Barraclough H; van Kooten M; Orlando M
    J Thorac Oncol; 2011 Nov; 6(11):1907-14. PubMed ID: 22005471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.